Comprehensive SWOT analysis reveals Gilead Sciences Inc's strategic positioning in the pharmaceutical industry. Financial ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today. The company’s ...

Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

at 06:50 Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly ... the company's injectable HIV-1 capsid inhibitor, for the... Fennec Pharmaceuticals Inc. , a commercial stage specialty ...

Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

Democratic Party leaders and their donors bear responsibility for the increasingly widespread view of trans rights as ...

As Modern Healthcare reports, CMS has relaxed supervision requirements for physical and occupational therapist assistants from “direct” to “general.” The change could help health systems manage ...

Screening rates for hepatitis D virus are not ideal among individuals with hepatitis B virus, who also have a higher all-cause mortality rate.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...